Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Last week's worst performers include CRCL, HIMS, VG, QXO, CRWV, DUOL, EQIX, EQNR, CF, and EC. Are they in your portfolio?

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

Tesla (NASDAQ: TSLA) CEO Elon Musk endorsed Microsoft (NASDAQ: MSFT) Satya Nadella's perspective on the practical impact of AI, emphasizing its benefits to sectors like healthcare, education, and productivity.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry.

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.

Retail sentiment surged on Stocktwits, with message volume jumping 1,600% for Abbott and 750% for Dexcom.

Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the stock.

Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry.

Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio.

On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday.